Mr Chris Blick

Academic Background

Mr Chris Blick carried out his specialist urological training in the Oxford deanery within the hospitals of Oxfordshire, Berkshire, and Buckinghamshire. He completed his specialist training with a British Association of Urological Surgeons Fellowship to the Keck Institute of Medicine, University of Southern California, USA. This was under the tutorship of Professor Inderbir Gill, a world renowned pioneer and international leader of robotic renal and bladder surgery. His team has the world’s most extensive experience of robotic renal and bladder surgery having carried out over 13,000 procedures.

Prior to specialist training, Mr Chris Blick was awarded competitive fellowship grants by The Royal College of Surgeons, The Urology Foundation and UCare. This supported 3 years of full time laboratory based scientific research in kidney and bladder cancer. Following this, Mr Chris Blick has published extensively in the clinical and scientific literature on kidney and bladder cancer and after completing his thesis was awarded a DPhil (PhD) by Christ Church, University of Oxford.

During specialist training, Mr Chris Blick was elected by his peers as Chairman of the Specialist Urology Registrars Group (SURG). Mr Blick represented the views and educational needs of all the UK and Irish specialist urological trainees / residents over the 3 years of his chairmanship.

Professional Profile

Mr Chris Blick is a Consultant Urological Surgeon who has a subspeciality interest in urological cancers, particularly laparoscopic and robotic renal, ureteric and bladder surgery.

Mr Blick has an interest in the treatment of benign prostatic enlargement using Aquablation, Rezum and UroLift technology.

Mr Chris Blick also has a particular interest in clinical trials. He was successful in becoming the first urological trainee member of the National Institute of Heath Research (NIHR) clinical studies group (CSG). He currently sits on the national renal and bladder cancer CSG, the screening and early prevention (SPED) group and the UK cancer screening and early prevention group of the NIHR.

He is the Research and Development Lead in Urology at the Royal Berkshire Hospital. He has recently received funding and is Chief Investigator in the TARGET trial using augmented reality and artificial intelligence in the diagnosis of prostate cancer. He is also UK Chief Investigator for the EASE Trial examining the role of active surveillance in renal cancer.